Physician profile
James Keffer
NPI 1013980168
$1,139.91
in general payments reported to CMS, 2019-2025
29 companies · $51.38 in 2025
The $51.38 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $130 · 2021: $248 · 2022: $92.87 · 2023: $302 · 2024: $135 · 2025: $51.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $171.73 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $98.21 | 2019-2021 | |
| Pfizer INC. | $90.50 | 2021-2023 | |
| Emd Serono, INC. | $75.36 | 2023-2024 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $72.59 | 2023-2024 | Gammagard, Hyqvia |
| Abbvie INC. | $67.88 | 2022-2024 | |
| Almatica Pharma LLC | $62.20 | 2021 | |
| Assertio Therapeutics, INC. | $48.05 | 2019 | |
| Redhill Biopharma INC. | $43.05 | 2021-2022 | |
| Genentech USA, INC. | $40.66 | 2023 | Ocrevus, Enspryng |
| Otsuka America Pharmaceutical, INC. | $38.97 | 2023-2024 | Nuedexta |
| Averitas Pharma INC. | $37.56 | 2025 | Qutenza |
| Forte Bio-Pharma LLC | $25.63 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $23.24 | 2023 | Rytary |
| Nevro Corp. | $22.68 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $20.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.26 | 2019 | |
| Lilly USA, LLC | $17.27 | 2024 | Emgality |
| Alnylam Pharmaceuticals INC. | $16.84 | 2023 | Onpattro |
| Eisai INC. | $16.72 | 2024 | |
| Medtronic USA, INC. | $16.64 | 2019 | |
| Boston Scientific Corporation | $16.49 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.94 | 2023 | Ajovy |
| Spinal Simplicity, LLC | $14.87 | 2022 | |
| Virtus Pharmaceuticals LLC | $14.76 | 2021 | |
| Surgalign Spine Technologies, INC. | $14.33 | 2019 | |
| Medtronic, INC. | $13.82 | 2025 | Kyphon Express II Kyphopak Tray |
| Astrazeneca Pharmaceuticals LP | $11.64 | 2019 | |
| Zyla Life Sciences, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Keffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.